# Nuvectis Pharma, Inc. (NVCT) — capital_raise/public_offering [announced]
Source: SEC API (secapi.ai) · situation sit_158b22f50d1dde061ef9 · retrieved 2026-08-11T16:10:44.563Z

## Overview
Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, with lead candidate ciprocopan (NXP100), a Complement Factor B inhibitor recently approved in China for PNH treatment.

Nuvectis Pharma completed a follow-on public offering in July 2026, raising $115 million in gross proceeds (including the exercise of the underwriters' overallotment). The offering was anchored by leading healthcare dedicated investors and extends the company's cash runway into the first half of 2029.

## Terms
- Counterparty: Leading healthcare dedicated investors · Deal value: $115.0M · Consideration: cash

## Key dates
- Announced 2026-08-04

## Timeline
- 2026-08-04 · 8-K (0001104659-26-090094): 8-K - Nuvectis Pharma, Inc. — *Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, with lead candidate ciprocopan (NXP100), a Complement Factor B inhibitor recently approved in China for PNH treatment.* Nuvectis Pharma completed a follow-on public offering in July 2026, raising $115 million in gross proceeds (including the exercise of the underwriters' overallotment). The offering was anchored by leading healthcare dedicated investors and extends the company's cash runway into the first half of 2029.
  https://www.sec.gov/Archives/edgar/data/1875558/0001104659-26-090094.txt

## Citations
- 0001104659-26-090094 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926090094